Allogene Therapeutics Inc.

(ALLO) Trade

By |

Profile

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Contact Information

Website: www.allogene.com
Email: IR@allogene.com
Main Phone: +1 650 457-2700
Address: 210 East Grand Avenue
State: CA
City / Town: South San Francisco
Country: USA
Postal Code: 94080

Issuer Information

Exchange: NGS
CEO: David D. Chang
Employees: 190
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

Profile

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Contact Information

Website: www.allogene.com
Email: IR@allogene.com
Main Phone: +1 650 457-2700
Address: 210 East Grand Avenue
State: CA
City / Town: South San Francisco
Country: USA
Postal Code: 94080

Issuer Information

Exchange: NGS
CEO: David D. Chang
Employees: 190
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

$ 23.41 $ -1.31 (-5.30%)
Last Price 23.41 Change $ -1.31 Change % -5.30 Tick N/A
Bid N/A Bid Size 0.00 Ask 25.70 Ask Size 3,400.00
Open 24.71 High 24.95 Low 23.30 Prev Close 24.72
Last Trade Volume 769,831 52 Wk Hi 33.80 52 Wk Low 23.30
Market Cap 2.9 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 121,902,101.00 EPS (TTM) -6.95 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 14 14
Number of Buys 14 14
Number of Sells 0 0
Net Activity 31051496 31051496
Last 10 Buys Shares
Franz Bernard Humer 1,000
Owen N. Witte 1,000
David D. Chang 1,000
Arie S. Belldegrun 1,000
James G. Coulter 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 31
Low Target Price Estimate 29
Mean Target Price Estimate 30
Standard Deviation 1.41
Date of Most Recent Estimate 11/05/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 0 0 0
Moderate Buy 0 0 0 0
Hold 1 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.67 0 0 0